Risk factors
Summit Therapeutics (SMMT) risk factors
Item 1A of every Summit Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors71 risks5 new5 dropped18 reworded
Summit added risks regarding foreign clinical data acceptance, Medicare Part B and D inflation rebates, and MFN price targets under a 2025 Executive Order.
Filed Feb 23, 2026 - FY2024 10-K risk factors71 risks
Summit relies entirely on ivonescimab, licensing it from Akeso with billions in potential milestone payments. Clinical trials, regulatory approvals, and manufacturing depend heavily on third-party contractors in China and elsewhere. The company has incurred significant operating losses and requires ongoing external capital to survive.
Filed Feb 24, 2025